Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hrain Biotech Raises $28 Million in B Round for Immunotherapies

publication date: Oct 1, 2019

Shanghai Hrain Biotechnology, a clinical-stage oncology immunotherapy company, raised $28 million in a Series B round led by Shenzhen Capital. Hrain is located in Shanghai's Zhangjiang Hi-Tech Park. Founded in 2015 by returnees, the company has "one center and multiple highlights." Its major emphasis is CAR-T products, but it also is developing other products using CAR-Natural Killer Cells, dendritic cell-based cancer vaccines. and invariant natural killer T cells. Hrain has started China clinical trials for two of its CAR-T therapies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital